Cargando…

Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C

Chronic infection with the hepatitis C virus (HCV) remains a major health problem affecting approximately 58 million people worldwide. In the era of interferon (IFN)-based regimens, patients particularly infected with genotypes 1 and 4 achieved a low response rate. The implementation of direct-actin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brzdęk, Michał, Zarębska-Michaluk, Dorota, Invernizzi, Federica, Cilla, Marta, Dobrowolska, Krystyna, Flisiak, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950869/ https://www.ncbi.nlm.nih.gov/pubmed/36844142 http://dx.doi.org/10.3748/wjg.v29.i6.949

Ejemplares similares

Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?
por: Pabjan, Paweł, et al.
Publicado: (2022)

Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders
por: Dybowska, Dorota, et al.
Publicado: (2023)

COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Pangenotypic triple versus double therapy in HCV-infected patients after prior failure of direct-acting antivirals
por: Flisiak, Robert, et al.
Publicado: (2023)

Early oral antiviral use in patients hospitalised with COVID-19
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Retrospective Analysis of the Effectiveness of Remdesivir in COVID-19 Treatment during Periods Dominated by Delta and Omicron SARS-CoV-2 Variants in Clinical Settings
por: Dobrowolska, Krystyna, et al.
Publicado: (2023)

Ways to Eliminate Viral Hepatitis as a Global Health Threat
por: Flisiak, Robert, et al.
Publicado: (2022)

Perspectives of hepatitis C virus (HCV) elimination in Poland
por: Flisiak, Robert, et al.
Publicado: (2019)

Real-World Efficacy and Safety of an 8-Week Glecaprevir/Pibrentasvir Regimen in Children and Adolescents with Chronic Hepatitis C—Results of a Multicenter EpiTer-2 Study
por: Pawlowska, Malgorzata, et al.
Publicado: (2023)

Real-World Effectiveness and Safety of Direct-Acting Antivirals in Patients with Chronic Hepatitis C and Epilepsy: An Epi-Ter-2 Study in Poland
por: Pazgan-Simon, Monika, et al.
Publicado: (2023)

Updates in Management of SARS-CoV-2 Infection
por: Flisiak, Robert, et al.
Publicado: (2022)

Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens
por: Tronina, Olga, et al.
Publicado: (2023)

Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Viral hepatitis C treatment shortening – what is the limit?
por: Zarębska-Michaluk, Dorota
Publicado: (2019)

Genotype 3-hepatitis C virus’ last line of defense
por: Zarębska-Michaluk, Dorota
Publicado: (2021)

Searching for the optimal population for hepatitis C virus screening in Poland
por: Piekarska, Anna, et al.
Publicado: (2020)

Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era
por: Brzdęk, Michał, et al.
Publicado: (2023)

Real-world direct-acting antiviral treatment in kidney transplant and hemodialysis patients: the EpiTer-2 multicenter observational study
por: Tronina, Olga, et al.
Publicado: (2021)

Changing Epidemiological Patterns of Infection and Mortality Due to Hepatitis C Virus in Poland
por: Genowska, Agnieszka, et al.
Publicado: (2023)

Change in the Clinical Picture of Hospitalized Patients with COVID-19 between the Early and Late Period of Dominance of the Omicron SARS-CoV-2 Variant
por: Flisiak, Robert, et al.
Publicado: (2023)

Variability in the Clinical Course of COVID-19 in a Retrospective Analysis of a Large Real-World Database
por: Flisiak, Robert, et al.
Publicado: (2023)

Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2023
por: Tomasiewicz, Krzysztof, et al.
Publicado: (2023)

Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance
por: Flisiak, Robert, et al.
Publicado: (2022)

Correction: Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance
por: Flisiak, Robert, et al.
Publicado: (2022)

Trends of infections and mortality due to hepatitis B virus (2005-2022) and the potential impact of the COVID-19 pandemic: a population-based study in Poland
por: Genowska, Agnieszka, et al.
Publicado: (2023)

Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals
por: Howe, Anita Y.M., et al.
Publicado: (2022)

Does Hospitalization Change the Perception of COVID-19 Vaccines among Unvaccinated Patients?
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

The Course of COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases
por: Rorat, Marta, et al.
Publicado: (2022)

Oral antiviral treatments for COVID-19: opportunities and challenges
por: Rahmah, Laila, et al.
Publicado: (2022)

Correction: Oral antiviral treatments for COVID-19: opportunities and challenges
por: Rahmah, Laila, et al.
Publicado: (2022)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012)

Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)

How close are we to hepatitis C virus elimination in Central Europe?
por: Flisiak, Robert, et al.
Publicado: (2020)

Retreatment of symptomatic hepatitis C virus genotype 3 associated mixed cryoglobulinemia with sofosbuvir and ribavirin: a case report
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2018)

Obligation Is Not a Compulsion—The Quality of the Law and the Effectiveness and Safety of Vaccination against COVID-19
por: Kocańda, Kamila, et al.
Publicado: (2022)

Effect of COVID-19 on Anti-S Antibody Response in Healthcare Workers Six Months Post-Vaccination
por: Flisiak, Robert, et al.
Publicado: (2021)

Clinical Characteristics of Hospitalized COVID-19 Patients Who Received at Least One Dose of COVID-19 Vaccine
por: Rzymski, Piotr, et al.
Publicado: (2021)

Psychiatric treatment considerations with direct acting antivirals in hepatitis C
por: Sockalingam, Sanjeev, et al.
Publicado: (2013)

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
por: Ahmed, Asma, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_cif54mllbp221gmehsaep0j8k4